Health & Biotech
Neurotech International Limited (ASX:NTI) is a clinical-stage biopharmaceutical development company focused predominately on paediatric neurological disorders, where there is persistent neuroinflammation. Neurotech has completed a Phase I/II clinical trial in Autism Spectrum Disorder (ASD), which demonstrated excellent safety and efficacy results at 28 days, 20 weeks and 52 weeks of treatment with NTI164. The Company commenced Phase II/III randomised, double-blind, placebo controlled clinical trial in ASD in Q4 CY2022. Neurotech is also conducting additional Phase I/II trials in Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and Paediatric Acute-Onset Neuropsychiatric Syndrome (PANS), collectively PANDAS/PANS, along with Rett Syndrome and Cerebral Palsy during CY2023.
NTI164 is a proprietary drug formulation derived from a unique cannabis strain with low THC (M<0.3%) and a novel combination of cannabinoids including CBDA, CBC, CBDP, CBDB and CBN.
NTI164 has been exclusively licenced for neurological applications globally. Pre-clinical studies have demonstrated a potent anti-proliferative, anti-oxidative, anti-inflammatory and neuro-protective effects in human neuronal and microglial cells. NTI164 is being developed as a therapeutic drug product for a range of neurological disorders in children where neuroinflammation is involved.
KEY PEOPLE
RELATED STOCKHEAD STORIES
Stockhead TV
What’s in store for 2024: Neurotech International
Health & Biotech
Weed Week: Blow to cannabis as Thailand backpedals on weed law; and recent ASX pot stock winners
Health & Biotech
Part 1: ASX biotechs with catalysts looking to pop in 2024
Health & Biotech
Weed Week: Cannabis stocks down almost 20pc in 2023, but here’s why they could rebound by Q2 2024
News
In Case You Missed It: New niobium and REE projects plus scaffold distribution deals
Health & Biotech
Neurotech completes recruitment in Phase 2/3 autism spectrum disorder trial
Health & Biotech
ASX Health Stocks: dorsaVi up 27pc on US deals, Starpharma reports positive outcome on Phase 2 trial
Health & Biotech
Weed Week: Cannabis boom a ‘matter of when, not if’; and NSW to allow residents to grow pot
News
In Case You Missed It: Home sleep test nabs FDA approval
Health & Biotech
Neurotech to extend Phase 2/3 autism spectrum disorder trial to adults
Health & Biotech
ASX Health Stocks: Compumedics granted FDA clearance; Botanix receives FDA feedback
Health & Biotech
Weed Week: Massive study links cannabis to genetics and schizophrenia, and the best ASX weed stocks right now
Health & Biotech
Why these ASX firms are shying away from the pot stock label – Part Two
News
Rise and Shine: Everything you need to know before the ASX opens
Health & Biotech
Q+A: Neurotech’s Dr Thomas Duthy on commercialising NTI164 as a treatment for PANDAS/PANS
News
Quarterly wrap: Incannex and Neurotech focus on advancing clinical trials
Health & Biotech